SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 eFFECTOR Therapeutics, Inc. , a leader in the development of selective translation regulator inhibitors for the treatment of cancer,.
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer, results from a recent clinical trial show.
Latest Articles freerepublic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freerepublic.com Daily Mail and Mail on Sunday newspapers.
A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer, results from a recent clinical trial show.